inVentiv Group Holdings has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No pricing details were mentioned in the filing, but the offering is valued up to $100 million, although this number is usually just a placeholder. The company has not yet decided on an exchange or symbol for its listing.
The underwriters for the offering are Credit Suisse, Morgan Stanley, Goldman Sachs, Jefferies, Citigroup, Merrill Lynch, Barclays and Wells Fargo.
This is a leading global provider of outsourced clinical development and commercialization services to biopharmaceutical companies. The company is the only provider delivering a full suite of services to enhance clients’ ability to successfully develop, launch and market their products. It offers services on both a standalone basis and as integrated solutions to support clinical development and commercialization.
These solutions are designed to drive greater efficiency and lower costs. inVentiv helped develop or commercialize over 80% of all new molecular entities approved by the U.S. Food and Drug Administration (FDA) and 70% of those approved by the European Medicines Agency (EMA) over the past five years through its innovative model.
In 2015, it served more than 550 client organizations, including all 20 of the largest global biopharmaceutical companies, and it has the ability to service clients in over 90 countries. The company has over 14,000 employees globally, including over 750 M.D.s and Ph.D.s.
In terms of finances, the company’s net revenues increased 10.4% on an as-reported basis (13.0% on a constant currency basis) to $1.994 billion. Clinical segment net revenues increased 8.9% to $947.9 million, and Commercial segment net revenues increased 12.3% to $1.06 billion. The company incurred losses from continuing operations of $150.6 million and $180.6 million for 2015 and 2014, respectively.
inVentiv intends to use the net proceeds from this offering to repay certain outstanding indebtedness and for general corporate purposes.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.